Back

State of the art in treatment of acute coronary syndrome patients in need of oral anticoagulation.

30 August 2016 (08:30 - 08:48)
Organised by:
Congress Presentation Part of: Challenges with anticoagulants and antithrombotics in acute coronary syndrome Infarction acute phase STEMI ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Willem Dewilde

Imelda Hospital, Bonheiden (Belgium)

4 More presentations in this session

Presentation thumbnail
Comparative impact of preexisting and new-onset atrial fibrillation on long-term mortality in STEMI patients admitted for primary PCI
Doctor I. Veljic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Incidence, presentation, treatment and outcome of patients with myocardial infarction type 2 in routine clinical practice
Doctor D. Radovanovic (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
New onset atrial fibrillation in st-segment elevation myocardial infarction: predictors and impact on therapy and mortality
Doctor K. Hyde Congo (Evora, PT)
Abstract Slides Video
Presentation thumbnail
Future direction for research in treatment of acute coronary syndrome patients in need of oral anticoagulation.
Doctor M. Lettino (Monza, IT)
Slides Video

Access the full session

Session thumbnail
Challenges with anticoagulants and antithrombotics in acute coronary syndrome

The Event

Event poster

ESC Congress 2016

30 August 2016 08:30 CET
You may be interested in
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?
14 March 2025
thumbnail
Congress Presentation
Use of Non-vitamin K antagonist Oral Anticoagulants in a real-world setting: a community pharmacy-based study.
31 August 2019
thumbnail
Congress Presentation
Oral anticoagulation monotherapy versus combination antithrombotic therapy in patients with AF and PCI with a drug-eluting stent implantation: a systematic review and meta-analysis
23 April 2026
thumbnail
Webinar
Anticoagulation challenges in older subjects with multimorbidity
25 July 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources